The elevated expression and activity of YAP1, a pivotal downstream effector of the Hippo pathway, are associated with tumor growth, metastasis, therapy resistance, and poor prognosis in various human cancers, including HCC [7, 8, 17, 24, 25]. Here, YAP1 is linked to cancer.